As pharma and biopharma researchers race to develop treatments for COVID-19, commercial leaders must prepare now to ensure success in the market. Independent biopharma consultant Marc Cooley—who helps companies bring commercial planning efforts into the R&D process—joins us to discuss the commercial considerations that life science companies should keep in mind as they develop COVID-19 vaccines and therapies.

Hosted on Acast. See acast.com/privacy for more information.